Abstract
With the incidence of cardiac disease on a constant growth curve, a test
modality that can provide specific, inexpensive screening tools for
cardiovascular disease (CVD) before the onset of symptoms, is like the
proverbial "license to print money," and a large menu of tests have been
developed, including serum lipids, hypercoagulation factors, enzyme and
protein markers, genetic makeup, and even tests for certain viral infections.
This report presents diagnostic modalities for the detection of CVD throughout
the continuum of the disease progression including: congestive heart failure,
unstable angina, myocardial infarction, stroke and other manifestations of CVD.
The report provides data on the world market for cardiovascular disease
markers in U.S. dollars with projections to 2010. Specific segments covered,
include:
- Cholesterol/Lipid Markers (Laboratory)
- Cholesterol/Lipid Markers (POC Professional)
- Cholesterol/Lipid Markers (POC OTC)
- C-Reactive Protein/Inflammation Markers
- Enzymes, Special
- Acute Myocardial Infarction Enzymes(Laboratory)
- Acute Myocardial Infarction (POC)
- BNP
- Coagulation Markers
- Homocysteine
- D-Dimer
- Gene Thrombophilia Markers
The report also discussed the clinical, regulatory, and business trends
shaping test research, development, and marketing, and profiles the CVD
offerings and positions of 46 top companies and innovators worldwide.
View Cart
